Log In
Print
BCIQ
Print
Print this Print this
 

EX-527, SEN0014196

  Manage Alerts
Collapse Summary General Information
Company Elixir Pharmaceuticals Inc.
DescriptionOral, sirtuin 1 (SIRT1) inhibitor
Molecular Target Sirtuin 1 (SIRT1)
Mechanism of ActionSirtuin 1 (SIRT1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHuntington's disease (HD)
Indication DetailsTreat Huntington's disease (HD)
Regulatory Designation

U.S. - Orphan Drug (Treat Huntington's disease (HD));
EU - Orphan Drug (Treat Huntington's disease (HD))

Partner

Siena Biotech S.p.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today